Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Sacituzumab Govitecan-hziy
Related studies linked through entity extraction aliases.
A Study of Sacituzumab Govitecan in People With Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Sacituzumab Govitecan in Patients With Solid Tumor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
- Status
- WITHDRAWN
- Phase
- PHASE2
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- Status
- RECRUITING
- Phase
- PHASE1
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- Status
- COMPLETED
- Phase
- PHASE3
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of DF1001 in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2